Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest GeNO LLC Stories

2013-08-27 08:28:02

Dr. Kurt Dasse named Chief Executive Officer, Dr. David Fine to serve as Executive Chairman and Chief Scientific Officer WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of...

2013-01-29 08:30:21

WALTHAM, Mass., Jan. 29, 2013 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held pharmaceutical company developing a line of innovative nitric oxide drug products, today announced that new pre-clinical and clinical data from studies of GeNO's nitric oxide delivery systems will be presented at the American College of Cardiology's Annual Scientific Session in March 2013, and at the American Thoracic Society International Conference in May 2013. GeNO's preclinical and clinical data...

2012-12-18 12:27:51

Dasse named President; Gellman named Senior Vice President, Engineering WALTHAM, Mass., Dec. 18, 2012 /PRNewswire/ -- GeNO LLC, a privately held pharmaceutical company that is developing innovative nitric oxide (NO) generation and delivery platforms, today announced that Kurt Dasse, a member of the company's Board of Managers and formerly Executive Vice President, has been appointed President of GeNO. Prior to joining GeNO, he served as President and CEO of Waltham, Massachusetts based...

2012-11-13 08:34:53

WALTHAM, Mass., Nov. 13 , 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com) today announced that its New Drug Application (NDA) for GeNOsyl(TM) MVG-2000 Nitric Oxide Delivery System for neonates with hypoxic respiratory failure, which was filed on August 31, 2012, has been accepted for filing by the U.S. Food and Drug Administration (FDA). "We are pleased with the FDA's acceptance of our NDA submission for review as it is a significant achievement in the regulatory approval process," said...

2012-08-21 06:27:11

WALTHAM, Mass., Aug. 21, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held pharmaceutical company developing a line of inhaled nitric oxide drug products, today announced it has been awarded four (4) additional US patents on its proprietary nitric oxide (NO) generation chemistry and delivery technology. This brings to sixteen (16) the number of US patents that have been awarded to GeNO, with additional patents pending. US patent number 8,211,368, which expires in 2028,...

2012-08-14 02:30:15

WALTHAM, Mass., Aug. 14, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held pharmaceutical company developing a line of inhaled nitric oxide drug products, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its nitric oxide (delivered via the GeNOsyl MVG-2000 delivery system) for the treatment of persistent pulmonary hypertension in newborns (PPHN). The orphan drug designation was granted based on a plausible hypothesis...

2012-08-09 06:26:19

WALTHAM, Mass., Aug. 9, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held pharmaceutical company developing a line of inhaled nitric oxide drug products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market its inhaled nitric oxide (NO) delivery system (GeNOsyl(TM) MV-1000). The GeNOsyl(TM) MV-1000 delivery system incorporates four components: the primary delivery system, a backup system, the NO gas analyzer, and the NO(2) gas...

2012-07-31 02:27:33

WALTHAM, Ma., July 31, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held biotechnology company developing a line of inhaled nitric oxide drug products, today announced it has been awarded two new US patents on its proprietary nitric oxide (NO) generation and delivery technology. This brings to twelve (12) the number of US patents that have been awarded to GeNO. US patent number 8,173,072 describes the conversion of nitrogen dioxide (NO(2)) to nitric oxide (NO) in a gas stream...

2012-04-19 06:26:47

COCOA, Fla., April 19, 2012 /PRNewswire/ -- New data presented today studied the safety of the GeNO system for delivering inhaled nitric oxide (NO) to patients being evaluated for cardiac transplant. GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, announced that a study of GeNO's NITROSYL Delivery System during Right Heart Catheterization (RHC) in subjects being evaluated for Orthotopic Heart Transplantation (OHT) and Left Ventricular Assist...

2012-04-11 02:25:04

COCOA, Fla., April 11, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced that data on the NITROSYL Delivery System during Right Heart Catheterization (RHC) in subjects being evaluated for Orthotopic Heart Transplantation (OHT) and Left Ventricular Assist Device (LVAD) implantation has been selected for oral presentation at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting in...